GTHP · Guided Therapeutics Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | - | $60.0K | $117.0K | $0 | - | $0 | $0 | $6.0K | - |
| Cost of Revenue | $0 | - | $25.0K | $38.0K | $0 | - | $0 | $0 | $2.0K | - |
| Gross Profit | $0 | - | $35.0K | $79.0K | $0 | - | $0 | $0 | $4.0K | - |
| R&D | $45.0K | - | $136.0K | $133.0K | $74.0K | - | $111.0K | $222.0K | $54.0K | - |
| SG&A | $451.0K | - | $362.0K | $658.0K | $267.0K | - | $374.0K | $364.0K | $236.0K | - |
| Total Operating Expenses | $302.0K | - | $520.0K | $842.0K | $414.0K | - | $561.0K | $655.0K | $363.0K | - |
| D&A | $2.0K | - | - | - | $2.0K | - | - | - | $2.0K | - |
| Operating Income | ($302.0K) | - | ($485.0K) | ($763.0K) | ($414.0K) | - | ($561.0K) | ($655.0K) | ($359.0K) | - |
| Interest Expense | $151.0K | - | $129.0K | $157.0K | $147.0K | - | $108.0K | $75.0K | $64.0K | - |
| Income Tax | $0 | - | $0 | $0 | $0 | - | $0 | $0 | $0 | - |
| Net Income | ($500.0K) | - | ($742.0K) | ($811.0K) | ($427) | - | ($654.0K) | ($709.0K) | ($402.0K) | - |
| EPS - Basic | ($0.01) | - | ($0.01) | ($0.01) | ($0.01) | - | ($0.01) | ($0.01) | ($0.01) | - |
| EPS - Diluted | ($0.01) | - | ($0.01) | ($0.01) | ($0.01) | - | ($0.01) | ($0.01) | ($0.01) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $369.0K | $63.0K | $87.0K | $185.0K | $115.0K | $388.0K | $194.0K | $275.0K | $445.0K | $591.0K |
| Accounts Receivable | $4.0K | $4.0K | $6.0K | $8.0K | $2.0K | $3.0K | $2.0K | $2.0K | $7.0K | $7.0K |
| Inventory | $469.0K | $448.0K | $583.0K | $595.0K | $633.0K | $633.0K | $636.0K | $632.0K | $632.0K | $632.0K |
| Accounts Payable | $2.28M | $2.42M | $2.38M | $2.25M | $2.15M | $2.09M | $2.10M | $2.14M | $1.92M | $1.99M |
| Current Assets | $911.0K | $605.0K | $799.0K | $811.0K | $811.0K | $1.20M | $1.04M | $1.02M | $1.24M | $1.39M |
| Total Assets | $1.60M | $1.32M | $903.0K | $940.0K | $967.0K | $1.38M | $1.25M | $1.25M | $1.49M | $1.67M |
| Current Liabilities | $5.96M | $6.64M | $6.47M | $6.38M | $5.90M | $6.16M | $6.03M | $5.73M | $5.34M | $4.81M |
| Long-term Debt | $91.0K | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $6.78M | $7.33M | $6.55M | $6.41M | $6.00M | $6.27M | $6.17M | $5.92M | $5.51M | $5.47M |
| Stockholders' Equity | ($5.18M) | ($6.01M) | ($5.65M) | ($5.47M) | ($5.0K) | ($4.89M) | ($4.92M) | ($4.67M) | ($4.01M) | ($3.81M) |
| Retained Earnings | ($158.07M) | ($157.06M) | ($155.81M) | ($155.03M) | ($154.17M) | ($153.71M) | ($153.01M) | ($152.32M) | ($151.56M) | ($151.12M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($617.0K) | - | - | - | ($331.0K) | - | - | - | ($100.0K) | - |
| Investing Cash Flow | - | - | - | - | - | - | - | - | - | - |
| Financing Cash Flow | $923.0K | - | - | - | $58.0K | - | - | - | ($46.0K) | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | 58.3% | 67.5% | - | - | - | - | 66.7% | - |
| Operating margin | - | - | -808.3% | -652.1% | - | - | - | - | -5983.3% | - |
| EBITDA margin | - | - | - | - | - | - | - | - | -5950.0% | - |
| Net margin | - | - | -1236.7% | -693.2% | - | - | - | - | -6700.0% | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | 226.7% | 113.7% | - | - | - | - | 900.0% | - |
| SG&A / Revenue | - | - | 603.3% | 562.4% | - | - | - | - | 3933.3% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -31.2% | - | -82.2% | -86.3% | -0.0% | - | -52.4% | -56.7% | -26.9% | - |
| Return on equity | 9.7% | - | 13.1% | 14.8% | 8.5% | - | 13.3% | 15.2% | 10.0% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.15 | 0.09 | 0.12 | 0.13 | 0.14 | 0.19 | 0.17 | 0.18 | 0.23 | 0.29 |
| Quick ratio | 0.07 | 0.02 | 0.03 | 0.03 | 0.03 | 0.09 | 0.07 | 0.07 | 0.11 | 0.16 |
| Cash ratio | 0.06 | 0.01 | 0.01 | 0.03 | 0.02 | 0.06 | 0.03 | 0.05 | 0.08 | 0.12 |
| Leverage | ||||||||||
| Debt / Equity | -0.02 | - | - | - | - | - | - | - | - | - |
| Debt / Assets | 0.06 | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -2.0x | - | -3.8x | -4.9x | -2.8x | - | -5.2x | -8.7x | -5.6x | - |
| Equity multiplier | -0.31 | -0.22 | -0.16 | -0.17 | -192.32 | -0.28 | -0.25 | -0.27 | -0.37 | -0.44 |
| Liabilities / Assets | 4.23 | 5.54 | 7.25 | 6.82 | 6.20 | 4.55 | 4.94 | 4.73 | 3.69 | 3.28 |
| Efficiency | ||||||||||
| Asset turnover | 0.00 | - | 0.07 | 0.12 | 0.00 | - | 0.00 | 0.00 | 0.00 | - |
| Inventory turnover | 0.00 | - | 0.04 | 0.06 | 0.00 | - | 0.00 | 0.00 | 0.00 | - |
| Days sales outstanding | - | - | 37d | 25d | - | - | - | - | 426d | - |
| Days inventory outstanding | - | - | 8512d | 5715d | - | - | - | - | 115340d | - |
| Days payable outstanding | - | - | 34777d | 21660d | - | - | - | - | 351130d | - |
| Cash conversion cycle | - | - | -26229d | -15920d | - | - | - | - | -235364d | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | 326.8x | 168.5x | - | - | - | - | 1.1x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | -100.0% | - | - | -100.0% | -72.7% | - |
| Revenue CAGR (3y) | - | - | 171.4% | 186.0% | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | -4.9% | - | - | - | - | - | -19.7% | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | -69.2% | - |
| Operating income growth (YoY) | 27.1% | - | 13.5% | -16.5% | -15.3% | - | 10.0% | 56.5% | 57.4% | - |
| Net income growth (YoY) | -116996.0% | - | -13.5% | -14.4% | 99.9% | - | 3.4% | 54.5% | 53.7% | - |
| EPS growth (YoY) | 0.0% | - | 0.0% | 0.0% | 0.0% | - | 0.0% | 66.7% | 50.0% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -102843.5% | -22.8% | -14.8% | -17.2% | 99.9% | -28.5% | - | -40.8% | -40.5% | -32.0% |
Peer comparison
Same SIC group: Electromedical & Electrotherapeutic Apparatus
Comparing GUIDED THERAPEUTICS INC against the 5 most active filers in the same SIC group.